Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2007; 7(5):325-327
Advances in research on pleiotropic effects of statins
1. CHEN Shao-ping(Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China cspcsp67@sina.com)
2. QIN Yong-wen(Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China )
3. ZHENG Xing(Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China )
ABSTRACT  Pleiotropic effects of statins beyond cholesterol reduction are introduced. Viewing from experimental and clinical evidence, the advances in research on statins are expounded, which may prove beneficial to the treatment of diseases, such as pulmonary hypertension, heart failure, arrhythmia and renal diseases.
Welcome to PCAR! You are the number 1668 reader of this article!
Please cite this article as:
CHEN Shao-ping,QIN Yong-wen,ZHENG Xing,. Advances in research on pleiotropic effects of statins[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2007; 7(5): 325-327.
References:
1. Laufs U, Liao J K. Isoprenoid metabolism and the pleiotropic effects of statins[J]. Curr Atheroscler Rep, 2003,5(5):372-378
2. Rikitake Y, Liao J K. Rho GTPases, statins, and nitric oxide[J]. Circ Res, 2005,97(12):1232-1235
3. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine[J]. Arterioscler Thromb Vasc Biol, 2005,25(9):1767-1775
4. Hirooka Y, Shimokawa H. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases[J]. Am J Cardiovasc Drugs, 2005,5(1):31-39
5. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice[J]. Circ Res, 2003,93(9):884-888
6. Laufs U, Gertz K, Dirnagl U, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice[J]. Brain Res, 2002,942(1-2):23-30
7. Veillard N R, Mach F. Statins: the new aspirin?[J]. Cell Mol Life Sci, 2002,59(11):1771-1786
8. Nishimura T, Vaszar L T, Faul J L,et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J]. Circulation, 2003,108(13):1640-1645
9. Kao P N. Simvastatin treatment of pulmonary hypertension: an observational case series[J]. Chest, 2005,127(4):1446-1452
10. Krum H, Latini R, Maggioni A P, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT[J]. Int J Cardiol, 2007,119(1):48-53
11. Mozaffarian D, Nye R, Levy W C. Statin therapy is associ-ated with lower mortality among patients with severe heart failure[J]. Am J Cardiol, 2004,93(9):1124-1129
12. Mitchell L B, Powell J L, Gillis A M, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators(AVID) trial[J]. J Am Coll Cardiol, 2003,42(1):81-87
13. Ozaydin M, Varol E, Aslan S M, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion[J]. Am J Cardiol, 2006,97(10):1490-1493
14. Douglas K, O'Malley P G, Jackson J L. Meta-analysis: the effect of statins on albuminuria[J]. Ann Intern Med, 2006,145(2):117-124
15. Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downre-gulating NOX4 in db/db mice[J]. Kidney Int, 2007,72(4):473-480
16. Athyros V G, Mikhailidis D P, Papageorgiou A A, et al. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evalu-ation (GREACE) Study[J]. Curr Med Res Opin, 2002,18(8):499-502
17. Athyros V G, Papageorgiou A A, Elisaf M, et al. Statins and renal function in patients with diabetes mellitus[J]. Curr Med Res Opin, 2003,19(7):615-617
18. Schulz R. Pleiotropic effects of statins: acutely good, but chronically bad?[J]. J Am Coll Cardiol, 2005,45(8):1292-1294
19. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention[J]. Am Heart J, 2006,151(2):273-281
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口